Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
LIFESTYLE INVESTMENTS, LLC v. AMICUS THERAPEUTICS, INC. et al
Case Number:
3:15-cv-07350
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Carella Byrne
- Chimicles Schwartz
- Cohn Lifland
- Dilworth Paxson
- Gardy & Notis
- Kroll Heineman
- Levi & Korsinsky
- Lite DePalma
- Troutman Pepper
Companies
Sectors & Industries:
-
April 17, 2017
Drug Co. Investors Seek OK For Early $3.8M Settlement
A putative class of investors in Amicus Therapeutics Inc. who said the company's misleading statements about their interaction with the U.S. Food and Drug Administration amounted to securities fraud asked a New Jersey federal court on Friday to approve a $3.75 million settlement that would end the litigation before the court even considered dismissal.
-
October 08, 2015
Amicus Faces Shareholder Suit Over Rosy NDA Statements
Amicus Therapeutics Inc. misled investors about the prospects of a new drug to treat a rare genetic disease, then reversed course two weeks later and sent stock prices plummeting, a shareholder alleged Wednesday in a proposed class action in New Jersey federal court.